<qa>  What is the name of the group that receives taxanetrastuzuma- Arm I: Patients receive taxanetrastuzumab therapy for 6 weeks. While continuing taxanetrastuzumab therapy, patients then undergo 10 fractions of concurrent prophylactic cranial radiotherapy in the absence of disease progression or unacceptable toxicity. 